600 related articles for article (PubMed ID: 22262199)
1. The interplay of HER2/HER3/PI3K and EGFR/HER2/PLC-γ1 signalling in breast cancer cell migration and dissemination.
Balz LM; Bartkowiak K; Andreas A; Pantel K; Niggemann B; Zänker KS; Brandt BH; Dittmar T
J Pathol; 2012 Jun; 227(2):234-44. PubMed ID: 22262199
[TBL] [Abstract][Full Text] [Related]
2. β-Heregulin impairs EGF induced PLC-γ1 signalling in human breast cancer cells.
Rommerswinkel N; Keil S; Adawy A; Hengstler JG; Niggemann B; Zänker KS; Dittmar T
Cell Signal; 2018 Dec; 52():23-34. PubMed ID: 30165102
[TBL] [Abstract][Full Text] [Related]
3. Induction of cancer cell migration by epidermal growth factor is initiated by specific phosphorylation of tyrosine 1248 of c-erbB-2 receptor via EGFR.
Dittmar T; Husemann A; Schewe Y; Nofer JR; Niggemann B; Zänker KS; Brandt BH
FASEB J; 2002 Nov; 16(13):1823-5. PubMed ID: 12354693
[TBL] [Abstract][Full Text] [Related]
4. Survivin expression is regulated by coexpression of human epidermal growth factor receptor 2 and epidermal growth factor receptor via phosphatidylinositol 3-kinase/AKT signaling pathway in breast cancer cells.
Asanuma H; Torigoe T; Kamiguchi K; Hirohashi Y; Ohmura T; Hirata K; Sato M; Sato N
Cancer Res; 2005 Dec; 65(23):11018-25. PubMed ID: 16322251
[TBL] [Abstract][Full Text] [Related]
5. HER2 overexpression increases sensitivity to gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, through inhibition of HER2/HER3 heterodimer formation in lung cancer cells.
Hirata A; Hosoi F; Miyagawa M; Ueda S; Naito S; Fujii T; Kuwano M; Ono M
Cancer Res; 2005 May; 65(10):4253-60. PubMed ID: 15899817
[TBL] [Abstract][Full Text] [Related]
6. Distinct functional roles of Akt isoforms for proliferation, survival, migration and EGF-mediated signalling in lung cancer derived disseminated tumor cells.
Grabinski N; Bartkowiak K; Grupp K; Brandt B; Pantel K; Jücker M
Cell Signal; 2011 Dec; 23(12):1952-60. PubMed ID: 21777670
[TBL] [Abstract][Full Text] [Related]
7. Breast cancer expressing the activated HER2/neu is sensitive to gefitinib in vitro and in vivo and acquires resistance through a novel point mutation in the HER2/neu.
Piechocki MP; Yoo GH; Dibbley SK; Lonardo F
Cancer Res; 2007 Jul; 67(14):6825-43. PubMed ID: 17638894
[TBL] [Abstract][Full Text] [Related]
8. Degradation of HER2 by ansamycins induces growth arrest and apoptosis in cells with HER2 overexpression via a HER3, phosphatidylinositol 3'-kinase-AKT-dependent pathway.
Münster PN; Marchion DC; Basso AD; Rosen N
Cancer Res; 2002 Jun; 62(11):3132-7. PubMed ID: 12036925
[TBL] [Abstract][Full Text] [Related]
9. Phosphorylated EGFR and PI3K/Akt signaling kinases are expressed in circulating tumor cells of breast cancer patients.
Kallergi G; Agelaki S; Kalykaki A; Stournaras C; Mavroudis D; Georgoulias V
Breast Cancer Res; 2008; 10(5):R80. PubMed ID: 18822183
[TBL] [Abstract][Full Text] [Related]
10. PIKE mediates EGFR proliferative signaling in squamous cell carcinoma cells.
Xie Z; Jiang Y; Liao EY; Chen Y; Pennypacker SD; Peng J; Chang SM
Oncogene; 2012 Dec; 31(49):5090-8. PubMed ID: 22349826
[TBL] [Abstract][Full Text] [Related]
11. A role for phospholipase C-gamma-mediated signaling in tumor cell invasion.
Kassis J; Moellinger J; Lo H; Greenberg NM; Kim HG; Wells A
Clin Cancer Res; 1999 Aug; 5(8):2251-60. PubMed ID: 10473113
[TBL] [Abstract][Full Text] [Related]
12. Platycodin D inhibits migration, invasion, and growth of MDA-MB-231 human breast cancer cells via suppression of EGFR-mediated Akt and MAPK pathways.
Chun J; Kim YS
Chem Biol Interact; 2013 Oct; 205(3):212-21. PubMed ID: 23867902
[TBL] [Abstract][Full Text] [Related]
13. EGF receptor signalling is essential for electric-field-directed migration of breast cancer cells.
Pu J; McCaig CD; Cao L; Zhao Z; Segall JE; Zhao M
J Cell Sci; 2007 Oct; 120(Pt 19):3395-403. PubMed ID: 17881501
[TBL] [Abstract][Full Text] [Related]
14. Profiling signalling pathways in formalin-fixed and paraffin-embedded breast cancer tissues reveals cross-talk between EGFR, HER2, HER3 and uPAR.
Berg D; Wolff C; Malinowsky K; Tran K; Walch A; Bronger H; Schuster T; Höfler H; Becker KF
J Cell Physiol; 2012 Jan; 227(1):204-12. PubMed ID: 21391216
[TBL] [Abstract][Full Text] [Related]
15. Androgen-independent prostate cancer cells circumvent EGFR inhibition by overexpression of alternative HER receptors and ligands.
Carrión-Salip D; Panosa C; Menendez JA; Puig T; Oliveras G; Pandiella A; De Llorens R; Massaguer A
Int J Oncol; 2012 Sep; 41(3):1128-38. PubMed ID: 22684500
[TBL] [Abstract][Full Text] [Related]
16. Prolactin modulates phosphorylation, signaling and trafficking of epidermal growth factor receptor in human T47D breast cancer cells.
Huang Y; Li X; Jiang J; Frank SJ
Oncogene; 2006 Dec; 25(58):7565-76. PubMed ID: 16785991
[TBL] [Abstract][Full Text] [Related]
17. CUDC-101, a multitargeted inhibitor of histone deacetylase, epidermal growth factor receptor, and human epidermal growth factor receptor 2, exerts potent anticancer activity.
Lai CJ; Bao R; Tao X; Wang J; Atoyan R; Qu H; Wang DG; Yin L; Samson M; Forrester J; Zifcak B; Xu GX; DellaRocca S; Zhai HX; Cai X; Munger WE; Keegan M; Pepicelli CV; Qian C
Cancer Res; 2010 May; 70(9):3647-56. PubMed ID: 20388807
[TBL] [Abstract][Full Text] [Related]
18. A new model system identifies epidermal growth factor receptor-human epidermal growth factor receptor 2 (HER2) and HER2-human epidermal growth factor receptor 3 heterodimers as potent inducers of oesophageal epithelial cell invasion.
Fichter CD; Przypadlo CM; Buck A; Herbener N; Riedel B; Schäfer L; Nakagawa H; Walch A; Reinheckel T; Werner M; Lassmann S
J Pathol; 2017 Dec; 243(4):481-495. PubMed ID: 28940194
[TBL] [Abstract][Full Text] [Related]
19. Epidermal growth factor receptor coexpression modulates susceptibility to Herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation.
Diermeier S; Horváth G; Knuechel-Clarke R; Hofstaedter F; Szöllosi J; Brockhoff G
Exp Cell Res; 2005 Apr; 304(2):604-19. PubMed ID: 15748904
[TBL] [Abstract][Full Text] [Related]
20. Tea polyphenol (-)-epigallocatechin 3-gallate suppresses heregulin-beta1-induced fatty acid synthase expression in human breast cancer cells by inhibiting phosphatidylinositol 3-kinase/Akt and mitogen-activated protein kinase cascade signaling.
Pan MH; Lin CC; Lin JK; Chen WJ
J Agric Food Chem; 2007 Jun; 55(13):5030-7. PubMed ID: 17539658
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
